Chemomab Therapeutics (CMMB) Payables (2017 - 2025)
Chemomab Therapeutics posted quarterly Payables of $485000.0 for Q4 2025, down 23.38% year-on-year from $633000.0 in Q4 2024, and up 150.0% on a QoQ basis from $194000.0 in Q3 2025.
Chemomab Therapeutics (CMMB) has 9 years of Payables data on file, last reported at $485000.0 in Q4 2025.
- For the quarter ending Q4 2025, Payables fell 23.38% year-over-year to $485000.0; the trailing twelve-month figure through Dec 2025 stood at $485000.0 (down 23.38% YoY), and the FY2025 full-year result was $485000.0, down 23.38% from the prior year.
- Payables for Q4 2025 stood at $485000.0, up from $194000.0 in the prior quarter.
- Across five years, Payables topped out at $2.3 million in Q2 2023 and bottomed at $194000.0 in Q3 2025.
- The 5-year median for Payables is $682000.0 (2023), against an average of $1.0 million.
- The widest annual swing landed in 2021, when Payables surged 1336.56%; it then sank 76.23% in 2024.
- A 5-year view of Payables shows it stood at $1.3 million in 2021, then increased by 26.35% to $1.7 million in 2022, then plunged by 69.43% to $516000.0 in 2023, then climbed by 22.67% to $633000.0 in 2024, then slipped by 23.38% to $485000.0 in 2025.
- The last three Payables figures came in at $485000.0 (Q4 2025), $194000.0 (Q3 2025), and $378000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 300,549.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.05 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 83.00 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 10.62 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 8.69 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 489.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.03 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 126.63 Mn |
| 10 | Chemomab Therapeutics | 959.23 Mn | 948.86 Mn | - | 485,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 485,000.00 |
| Sep 30, 2025 | 194,000.00 |
| Jun 30, 2025 | 378,000.00 |
| Mar 31, 2025 | 490,000.00 |
| Dec 31, 2024 | 633,000.00 |
| Sep 30, 2024 | 386,000.00 |
| Jun 30, 2024 | 1.11 Mn |
| Mar 31, 2024 | 527,000.00 |
| Dec 31, 2023 | 516,000.00 |
| Sep 30, 2023 | 731,000.00 |
| Jun 30, 2023 | 2.35 Mn |
| Mar 31, 2023 | 2.22 Mn |
| Dec 31, 2022 | 1.69 Mn |
| Sep 30, 2022 | 1.25 Mn |
| Jun 30, 2022 | 1.43 Mn |
| Mar 31, 2022 | 1.49 Mn |
| Dec 31, 2021 | 1.34 Mn |
| Sep 30, 2021 | 481,000.00 |
| Jun 30, 2021 | 472,000.00 |
| Mar 31, 2021 | 2.08 Mn |
| Dec 31, 2020 | 93,000.00 |
| Sep 30, 2020 | 1.62 Mn |
| Jun 30, 2020 | 974,000.00 |
| Mar 31, 2020 | 602,000.00 |
| Dec 31, 2019 | 2.86 Mn |
| Sep 30, 2019 | 924,000.00 |
| Jun 30, 2019 | 383,000.00 |
| Dec 31, 2018 | 396,000.00 |
| Dec 31, 2017 | 160,000.00 |